KaNDy Therapeutics

KaNDy Therapeutics is a clinical-stage company that focuses on optimizing the potential of NT-814 in treating common chronic debilitating female sex-hormone related conditions, with its primary focus on treating several symptoms of the menopause.

KaNDy Therapeutics was a spin-off from NeRRe Therapeutics, which itself is a spin-off from GSK in 2017, and all the data and intellectual properties that were associated with NT-814 were transferred to KaNDy Therapeutics.

KaNDy Therapeutics works under the control of an experienced management team and it is backed by investors who are internationally recognized in life sciences : Fountain Healthcare Partners, Advent Life Sciences, Forbion Capital Partners, OrbiMed and Longitude Capital.